Literature DB >> 33572326

The Role of mTOR Signaling as a Therapeutic Target in Cancer.

Nadezhda V Popova1, Manfred Jücker2.   

Abstract

The aim of this review was to summarize current available information about the role of phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling in cancer as a potential target for new therapy options. The mTOR and PI3K/AKT/mTORC1 (mTOR complex 1) signaling are critical for the regulation of many fundamental cell processes including protein synthesis, cell growth, metabolism, survival, catabolism, and autophagy, and deregulated mTOR signaling is implicated in cancer, metabolic dysregulation, and the aging process. In this review, we summarize the information about the structure and function of the mTOR pathway and discuss the mechanisms of its deregulation in human cancers including genetic alterations of PI3K/AKT/mTOR pathway components. We also present recent data regarding the PI3K/AKT/mTOR inhibitors in clinical studies and the treatment of cancer, as well the attendant problems of resistance and adverse effects.

Entities:  

Keywords:  AKT; PI3K; cancer; mTOR; mutation; therapy

Year:  2021        PMID: 33572326      PMCID: PMC7916160          DOI: 10.3390/ijms22041743

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  184 in total

Review 1.  Regulation of mTOR by phosphatidic acid?

Authors:  David A Foster
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

2.  Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

Authors:  Jean-Charles Soria; Ho-Young Lee; Janet I Lee; Luo Wang; Jean-Pierre Issa; Bonnie L Kemp; Diane D Liu; Jonathan M Kurie; Li Mao; Fadlo R Khuri
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

3.  EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.

Authors:  Rohit Bhargava; William L Gerald; Allan R Li; Qiulu Pan; Priti Lal; Marc Ladanyi; Beiyun Chen
Journal:  Mod Pathol       Date:  2005-08       Impact factor: 7.842

Review 4.  The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.

Authors:  Jennifer L Hsu; Mien-Chie Hung
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

5.  The 3.2-Å resolution structure of human mTORC2.

Authors:  Alain Scaiola; Francesca Mangia; Stefan Imseng; Daniel Boehringer; Karolin Berneiser; Mitsugu Shimobayashi; Edward Stuttfeld; Michael N Hall; Nenad Ban; Timm Maier
Journal:  Sci Adv       Date:  2020-11-06       Impact factor: 14.136

Review 6.  The biology and clinical relevance of the PTEN tumor suppressor pathway.

Authors:  Isabelle Sansal; William R Sellers
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

8.  mTOR kinase structure, mechanism and regulation.

Authors:  Haijuan Yang; Derek G Rudge; Joseph D Koos; Bhamini Vaidialingam; Hyo J Yang; Nikola P Pavletich
Journal:  Nature       Date:  2013-05-01       Impact factor: 49.962

9.  Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.

Authors:  Sharmila Mallya; Briana A Fitch; J Scott Lee; Lomon So; Matthew R Janes; David A Fruman
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.752

Review 10.  Regulation of mTORC2 Signaling.

Authors:  Wenxiang Fu; Michael N Hall
Journal:  Genes (Basel)       Date:  2020-09-04       Impact factor: 4.096

View more
  28 in total

Review 1.  Regulated cell death (RCD) in cancer: key pathways and targeted therapies.

Authors:  Fu Peng; Minru Liao; Rui Qin; Shiou Zhu; Cheng Peng; Leilei Fu; Yi Chen; Bo Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

2.  Sirolimus treatment induces dose-dependent involution of the thymus with elevated cellular respiration in BALB/c mice.

Authors:  Saeeda Almarzooqi; Charu Sharma; Dhanya Saraswathiamma; Ahmed R Alsuwaidi; Noura Hadid; Abdul-Kader Souid; Alia Albawardi
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

Review 3.  The Pathways Underlying the Multiple Roles of p62 in Inflammation and Cancer.

Authors:  Paulina Hennig; Gabriele Fenini; Michela Di Filippo; Tugay Karakaya; Hans-Dietmar Beer
Journal:  Biomedicines       Date:  2021-06-22

4.  CWHM-1008 Induces Apoptosis and Protective Autophagy through the Akt/mTOR Axis in LUAD Cells.

Authors:  Jiao Zhang; Man-Yuan Li; Xiao Lu; Quan-Xing Liu; Dong Zhou; Gui-Xue Yang; Xiao-Qing Liu; Hong Zheng; Ji-Gang Dai
Journal:  J Oncol       Date:  2021-09-11       Impact factor: 4.375

5.  Dual Inhibition of mTORC1/2 Reduces Migration of Cholangiocarcinoma Cells by Regulation of Matrixmetalloproteinases.

Authors:  Katharina Joechle; Huda Jumaa; Kerstin Thriene; Claus Hellerbrand; Birte Kulemann; Stefan Fichtner-Feigl; Sven A Lang; Jessica Guenzle
Journal:  Front Cell Dev Biol       Date:  2022-01-13

Review 6.  Targeting PI3K/Akt/mTOR Pathway by Different Flavonoids: A Cancer Chemopreventive Approach.

Authors:  Torki A Zughaibi; Mohd Suhail; Mohammad Tarique; Shams Tabrez
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

Review 7.  Targeting PI3K/Akt signal transduction for cancer therapy.

Authors:  Yan He; Miao Miao Sun; Guo Geng Zhang; Jing Yang; Kui Sheng Chen; Wen Wen Xu; Bin Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-16

8.  Essential Role of CRIM1 on Endometrial Receptivity in Goat.

Authors:  Diqi Yang; Ai Liu; Yanyan Zhang; Sha Nan; Ruiling Yin; Qianghui Lei; Hongmei Zhu; Jianguo Chen; Li Han; Mingxing Ding; Yi Ding
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

9.  Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer.

Authors:  Anita Thomas; Sascha Reetz; Philipp Stenzel; Katrin Tagscherer; Wilfried Roth; Mario Schindeldecker; Martin Michaelis; Florian Rothweiler; Jindrich Cinatl; Jaroslav Cinatl; Robert Dotzauer; Olesya Vakhrusheva; Maarten Albersen; Stephan Macher-Goeppinger; Axel Haferkamp; Eva Juengel; Andreas Neisius; Igor Tsaur
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

10.  New models for defining prostate cancer biology and patient prognosis.

Authors:  James Brundage; Benjamin L Maughan
Journal:  Asian J Androl       Date:  2022 Jan-Feb       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.